Published on September 30, 2013 at 11:01 AM
Merck Canada is providing a $4 million grant to the Fonds de recherche du Québec - Santé (FRQS) for academic research as part of a commitment made in 2010 to inject $100 million over five years in biopharmaceutical R&D in Quebec. The FRQS grant will go toward supporting patient-oriented research conducted by the Strategy for Patient-Oriented Research initiative.
Merck Canada says that this latest grant brings their total contributions to date as part of their $100 million commitment to approximately $68 million. In December, they provided a grant as part of the same commitment in the amount of $943,000 to fund research conducted at Concordia University's Center for Structural and Functional Genomics. Likewise, last November they invested $12.5 million to fund research at three university-affiliated and hospital-based research centers in Montreal: the Research Institute of the McGill University Health Centre, the CHUM Research Centre, and the Montréal Heart Institute Research Centre.
"The initiatives we support are a part of our approach to research and development, which is about building collaborative research relationships," Thomas R. Cannell, DVM, president and managing director, Merck Canada, said in a statement. "In our view, private-public partnerships provide a fertile environment for innovation to grow and lead to new and efficient ways of caring for patients."
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.